Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the relations between anaplastic lymphoma kinase (<i>ALK</i>) and v-myc myelocytomatosis viral related oncogene neuroblastoma derived homolog (<i>MYCN</i>) protein expression and their prognostic roles in neuroblastoma tumours.
|
31542727 |
2020 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two out of six cases expressed ALK and one had the F1174 L mutation reported in childhood neuroblastoma.
|
31749253 |
2020 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple therapeutic approaches are being used to target MYCN, ALK, and TrkB, as well as GD2, a surface antigen present on the surface of neuroblastoma tumor cells.
|
31092383 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined treatment with alectinib and vorinostat might be a novel therapeutic option for NB harboring the ALK R1275Q mutation.
|
31262882 |
2019 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ALK overexpression and activation, in the absence of genetic mutation has also been described in NB.
|
31340081 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three hotspot residues (F1174, F1245, and R1275) account for 85% of mutant ALK seen in neuroblastoma.
|
30778092 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review the basic aspects of MYCN, Trk, and ALK in both neural development and in neuroblastoma.
|
30848386 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Altogether, this study provides novel insights into ALK mutation dynamics in a neuroblastoma model harbouring two ALK mutations.
|
31452835 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links.
|
31043380 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the Anaplastic lymphoma tyrosine kinase (ALK) gene are common in NB.
|
30605844 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through a case study of mutations in kinase domains of three proteins, namely, the anaplastic lymphoma kinase (ALK) in pediatric neuroblastoma patients, serine/threonine-protein kinase B-Raf (BRAF) in melanoma patients, and erythroblastic oncogene B 2 (ErbB2 or HER2) in breast cancer patients, we compare the two approaches above.
|
30982079 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although expression of ALK F1174L resulted in enhanced proliferation of sympathetic ganglion progenitors and increased the size of the sympathetic ganglia, it was insufficient to cause neuroblastoma.
|
31218818 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since most cases are in children under the age of 2, understanding the role and regulation of ALK during neural crest development is an important goal in addressing neuroblastoma tumorigenesis.
|
30803032 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Resistance to ALK Inhibitors in Neuroblastoma Is Regulated by BORIS.
|
31420353 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanisms of acquired resistance to ALK inhibition therapy in neuroblastoma have not yet been elucidated.
|
31614113 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Anaplastic Lymphoma Kinase (<i>ALK</i>) gene is frequently altered in NB, through copy number alterations and activating mutations, and represents a predisposition in NB-genesis when mutated.
|
31058082 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that alectinib is an effective inhibitor of ALK kinase activity in ALK addicted neuroblastoma and should be considered as a potential future therapeutic option for ALK-positive neuroblastoma patients alone or in combination with other treatments.
|
31334113 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK-amplified NBs were correlated with synchronous MYCN amplification and chromosome 1p deletion.
|
28326957 |
2019 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Studies have shown that native ALK protein is expressed on the surface of most neuroblastoma cells, providing an opportunity for development of immune-targeting strategies.
|
30867324 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data confirm that PIM1 overexpression decreases sensitivity to ALK inhibitors in NB, and suggests that combined front-line inhibition of ALK and PIM1 is a viable strategy for the treatment of ALK-positive NB independent of MYCN status.
|
31780656 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we have illustrated the dynamic conformational property of wild-type ALK as well as the kinase activation equilibrium variation induced by two neuroblastoma mutations (R1275Q and Y1278S) and ATP binding by performing enhanced sampling accelerated Molecular Dynamics (aMD) simulations.
|
29638111 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our IPP analysis provides insight into the proximal architecture of oncogenic ALK signaling by revealing IRS2 as an adaptor protein that links ALK to neuroblastoma cell survival through the Akt-FoxO3 signaling axis.
|
30459283 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We find that pY-GSK3 phosphorylation depends on anaplastic lymphoma kinase (ALK), a protein associated with neuroblastoma.
|
29555900 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, truncated ALK protein was also reported in neuroblastoma.
|
28665006 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focal aberrations affect genes known to be involved in neuroblastoma, such as ALK and LIN28B.
|
30375995 |
2018 |